DOMS Industries Management Guidance Tracker

Management reiterated revenue growth guidance of 18-20% for FY26, despite Q1 coming in higher at 26.4% due to UniLand consolidation.

Management reiterated full-year revenue growth guidance of 18-20%, noting that H1 growth was boosted by full consolidation of Unigland Healthcare.

Management expects to close FY26 at the upper end of the guided revenue growth range of 18-20%, with 9M growth already at 22.7%.

For FY27, management targets similar revenue growth of 18-20%, driven by volume growth from new capacities and full utilization of recent brownfield expansions.

EBITDA margin guidance maintained at 16.5%-17.5% for FY26, with Q1 margin at 17.6% trending towards the upper end.

Management expects EBITDA margins to remain in the 16.5-17.5% range, supported by operational efficiencies.

Capex for FY26 expected to be ₹210-225 crore, primarily for the 44-acre project and capacity additions across segments.

Consolidated capex of ~₹150 crore in H1 FY26; full-year capex expected in the ₹210-225 crore range.

Capital expenditure for FY27 is expected to be between ₹225-250 crore, similar to FY26 levels, primarily for the 44-acre greenfield project.

First building handover expected by end of Q3 FY26, with commercial production starting ~90 days later in Q4.

First building possession expected in Q4 FY26, with commercial production starting in Q1 FY27, initially for pencil capacity.

Commercial production from the first building of the 44-acre project is expected to start in Q2 FY27, with subsequent buildings coming online over the next 9 quarters.